Assessing The Cost-Effectiveness of Secukinumab Compared To Tnf Inhibitors As Second Line Biologic Treatment In Psoriatic Arthritis

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1113
https://www.valueinhealthjournal.com/article/S1098-3015(16)32479-2/fulltext
Section Title : Disease-Specific Studies
Section Order : 1042
First Page : A538
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32479-2&doi=10.1016/j.jval.2016.09.1113
HEOR Topics :
Tags :
Regions :